What Is Claimed Is:

1. Use of bupropion and dextromethorphan in the manufacture of a medicament for a combination therapy to rapidly relieve the symptoms of depression in a human being in need thereof, wherein the medicament is to be administered once daily or twice daily to the human being to achieve a therapeutic effect within 2 weeks of the first day that the medicament is to be administered, and wherein the human being is of Asian descent.

2. Use of bupropion and dextromethorphan in the manufacture of a medicament for a combination therapy to treat depression in a human being in need thereof, wherein the medicament is to be administered once daily or twice daily to the human being, and wherein the human being is of Asian descent.

3. The use of claim 1 or 2, wherein the human being is of Japanese descent.

4. The use of claim 1 or 2, wherein the human being is of Chinese descent.

5. The use of claim 1 or 2, wherein the human being is of Korean descent.

6. The use of any one of claims 1-5, wherein the medicament comprises:

about 105 mg of bupropion hydrochloride, or a molar equivalent amount of: 1) another salt form of bupropion or 2) the free base form of bupropion, and

is to be orally administered once daily or twice daily.

7. The use of any one of claims 1-6, wherein the medicament comprises:

44 mg to 46 mg of dextromethorphan hydrobromide, or a molar equivalent amount of: 1) another salt form of dextromethorphan or 2) the free base form of dextromethorphan, and

is to be orally administered once daily or twice daily.

8. The use of any one of claims 1-7, wherein the human being has previously had an inadequate response to at least one antidepressant therapy.

9. The use of any one of claims 1-8, wherein the depression is major depressive disorder.

10. The use of any one of claims 1-9, wherein the depression is treatment resistant depression.

11. The use of any one of claims 1-10, wherein the medicament is to be administered once daily or twice daily for at least 30 days.

12. The use of any one of claims 1-11, wherein the medicament is to be administered once daily or twice daily for at least 42 days.

13. The use of any one of claims 1-12, wherein the combination of the bupropion and the dextromethorphan results in the MADRS score reduced by at least 10% as compared with baseline.

14. The use of any one of claims 1-12, wherein the combination of the bupropion and the dextromethorphan results in the MADRS score reduced by at least 10% as compared with placebo.

15. The use of claim 1 or 2, wherein the medicament comprises 40 mg to 100 mg of the dextromethorphan and 100 mg to 200 mg of the bupropion.

16. The use of claim 15, wherein the medicament is to be orally administered to the human being one daily or twice daily.

17. The use of claim 1 or 2, wherein the medicament comprises: 60 mg to 100 mg of the dextromethorphan, and is to be administered once per day.

18. The use of claim 1 or 2, wherein the medicament comprises: 200 mg to 250 mg of the bupropion, and is to be administered once per day.

19. The use of claim 6, wherein the medicament comprises: about 105 mg of bupropion hydrochloride, and is to be orally administered once daily or twice daily.

20. The use of claim 7, wherein the medicament comprises: about 45 mg of dextromethorphan hydrobromide, and is to be orally administered once daily or twice daily.

21. The use of claim 1 or 2, wherein the medicament comprising the bupropion and the dextromethorphan provides greater efficacy in the human being than bupropion alone.